← Back to Search

Antiandrogen

CC-90011 for Prostate Cancer

Phase 1

Waitlist Available

Research Sponsored by Celgene

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, up to 1.5 years

Awards & highlights

Study Summary

This trial will test whether CC-90011 can make tumors sensitive to anti-hormonal therapy again by inducing androgen receptor expression.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, up to 1.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, up to 1.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 1.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Androgen Receptor

Secondary outcome measures

Assessment of anti-tumor activity

Safety and tolerability assessed by Adverse events (AEs)

Safety and tolerability assessed by dose-limiting toxicities (DLTs)

Trial Design

1Treatment groups

Experimental Treatment

Group I: CC-90011 in combination with Abiraterone and PrednisoneExperimental Treatment3 Interventions

Oral administration (PO) of CC-90011 monotherapy administered once per week (QW), for 4 weeks. From cycle 2 onwards, all participants will receive 60 mg of CC-90011 PO QW, in combination with 100 mg of abiraterone PO daily, and 5 mg of prednisone PO every 12 hours (10mg QD)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CC-90011

2020

Completed Phase 2

~100

Abiraterone

2012

Completed Phase 4

~2830

Prednisone

2014

Completed Phase 4

~2370

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor

633 Previous Clinical Trials

128,036 Total Patients Enrolled

5 Trials studying Prostate Cancer

1,270 Patients Enrolled for Prostate Cancer

Zariana Nikolova, MD, PhDStudy DirectorCelgene

5 Previous Clinical Trials

519 Total Patients Enrolled

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,501 Previous Clinical Trials

3,367,664 Total Patients Enrolled

13 Trials studying Prostate Cancer

3,921 Patients Enrolled for Prostate Cancer

Media Library

Abiraterone (Antiandrogen) Clinical Trial Eligibility Overview. Trial Name: NCT04628988 — Phase 1

Prostate Cancer Research Study Groups: CC-90011 in combination with Abiraterone and Prednisone

Prostate Cancer Clinical Trial 2023: Abiraterone Highlights & Side Effects. Trial Name: NCT04628988 — Phase 1

Abiraterone (Antiandrogen) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04628988 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has CC-90011 been the focus of prior scientific exploration?

"Presently, there are 366 ongoing trials involving CC-90011 with a hundred of those in the final phase. While most experiments concerning this drug are based out of Duarte, California, over 17 thousand sites worldwide have started research into this medication."

Answered by AI

What is the cutoff for participants being allowed to join this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical research is still in the recruitment process. It was initially posted on July 28th 2021 and recently updated on July 21st 2022. The study requires 10 patients from a single site."

Answered by AI

To what medical conditions is CC-90011 typically prescribed?

"CC-90011 is a therapeutic agent used to treat thyroiditis and other maladies including ulcerative colitis, cancerous growths, and varicella-zoster virus acute retinal necrosis."

Answered by AI

To what extent do the risks of CC-90011 outweigh its potential advantages?

"CC-90011 is a relatively new medication, so its safety score was assessed at 1. This reflects the fact that there are only limited clinical data supporting both efficacy and safety in this Phase 1 trial."

Answered by AI

Is there any vacancy for participants in this trial?

"According to the clinicaltrials.gov records, this study has been recruiting since its inception on July 28th 2021 and is still actively enrolling patients as of the latest update dated July 21st 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

2021. "A Study of CC-90011 and Comparators in Participants With Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04628988.